Dialysate dihydroxyphenylglycol as a window for in situ axoplasmic norepinephrine disposition.
To examine basal axoplasmic norepinephrine (NE) kinetics at the in situ cardiac sympathetic nerve ending, we applied a dialysis technique to the heart of anesthetized cats and performed the dialysate sampling with local administration of a pharmacological tool through a dialysis probe. The dialysis probe was implanted in the left ventricular wall, and dihydroxyphenylglycol (DHPG, an index of axoplasmic NE) levels were measured by liquid chromatogram-electrochemical detection. Control dialysate DHPG levels were 161+/-19 pg/ml. Pargyline (monoamine oxidase inhibitor, 1 mM) decreased the dialysate DHPG levels to 38+/-10 pg/ml. Further alpha-methyl-para-tyrosine, omega-conotoxin GVIA, desipramine (NE synthesis, release and uptake blockers) decreased the dialysate DHPG levels to 64+/-19, 106+/-15, 110+/-22 pg/ml, respectively. In contrast, reserpine (vesicle NE transport inhibitor, 10 microM) increased the dialysate DHPG levels to 690+/-42 pg/ml. Thus, NE synthesis, metabolism and recycling (release, uptake and vesicle transport) affected basal intraneuronal NE disposition at the nerve endings. Measurement of DHPG levels through a dialysis probe provides information about basal intraneuronal NE disposition at the cardiac sympathetic nerve endings. Yohimbine (alpha(2)-adrenoreceptor blocker, 10 microM) and U-521 (catechol-O-methyltransferase blocker, 100 microM) did not alter the dialysate DHPG levels. Furthermore, there were no significant differences in the reserpine induced DHPG increment between the presence and absence of desipramine (10 microM) or alpha-methyl-para-tyrosine (100 mg/kg i.p.). These results may be explained by the presence of two axoplasmic pools of NE, filled by NE taken up and synthesized, and by NE overflow from vesicle. The latter pool of NE may be closed to the monoamine oxidase system in the axoplasma.
Yamazaki
T
T
Department of Cardiac Physiology, Research Institute, National Cardiovascular Center, Suita, 565-8565, Osaka, Japan. yamazaki@ri.ncvc.go.jp
Akiyama
T
T
Kitagwa
H
H
Kawada
T
T
Sunagawa
K
K
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D001369:Axons / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002415:Cats; D003891:Desipramine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006321:Heart / Q000294:innervation*; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism*; D017551:Microdialysis; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology; D009638:Norepinephrine / Q000032:analysis / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010293:Pargyline / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D019805:alpha-Methyltyrosine / Q000494:pharmacology; D020866:omega-Conotoxin GVIA / Q000494:pharmacology
D018759:Adrenergic Uptake Inhibitors; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D014179:Neurotransmitter Uptake Inhibitors; D008734:Methoxyhydroxyphenylglycol; D019805:alpha-Methyltyrosine; D012110:Reserpine; D020866:omega-Conotoxin GVIA; D010293:Pargyline; D003891:Desipramine; C010117:3,4-dihydroxyphenylglycol; D009638:Norepinephrine